UBS Reiterates Buy Rating on CG Oncology (CGON)

May 18, 2026 10:17 AM

UBS analyst David Dai reiterated a Buy rating and $90.00 price target on CG Oncology (NASDAQ: CGON).The analyst commented, "CGON ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found